Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriers

The aim of this work was to design innovative nanostructured lipid carriers (NLCs) for the delivery of dexibuprofen (DXI) as an antiproliferative therapy against tumoral processes, and overcome its side effects. DXI-NLC samples were prepared with beeswax, Miglyol 812 and Tween 80 using high-pressure...

Full description

Bibliographic Details
Authors: Thiruchenthooran, Vaikunthavasan, Switalska, Marta, Bonilla Vidal, Lorena, Espina García, Marta, García López, María Luisa, Wietrzyk, Joanna, Sánchez-López, E. (Elena), Gliszczyńska, Anna
Format: article
Status:Published version
Publication Date:2022
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/204200
Online Access:https://hdl.handle.net/2445/204200
Access Level:Open access
Keyword:Antiinflamatoris no esteroïdals
Càncer
Nonsteroidal anti-inflammatory agents
Cancer
id ES_b2a880f291b39ff43bf5938400a73d25
oai_identifier_str oai:diposit.ub.edu:2445/204200
network_acronym_str ES
network_name_str España
repository_id_str
spelling Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriersThiruchenthooran, VaikunthavasanSwitalska, MartaBonilla Vidal, LorenaEspina García, MartaGarcía López, María LuisaWietrzyk, JoannaSánchez-López, E. (Elena) Gliszczyńska, AnnaAntiinflamatoris no esteroïdalsCàncerNonsteroidal anti-inflammatory agentsCancerThe aim of this work was to design innovative nanostructured lipid carriers (NLCs) for the delivery of dexibuprofen (DXI) as an antiproliferative therapy against tumoral processes, and overcome its side effects. DXI-NLC samples were prepared with beeswax, Miglyol 812 and Tween 80 using high-pressure homogenization. A two-level factorial design 24 was applied to optimize the formulation, and physicochemical properties such as particle size, zeta potential, polydispersity index and entrapment efficiency were measured. Optimized parameters of DXI-NLCs exhibited a mean particle size of 152.3 nm, a polydispersity index below 0.2, and high DXI entrapment efficiency (higher than 99%). Moreover, DXI-NLCs provided a prolonged drug release, slower than the free DXI. DXI-NLCs were stable for 2 months and their morphology revealed that they possess a spherical shape. In vitro cytotoxicity and anticancer potential studies were performed towards prostate (PC-3) and breast (MDA-MB-468) cancer cell lines. The highest activity of DXI-NLCs was observed towards breast cancer cells, which were effectively inhibited at 3.4 μM. Therefore, DXI-NLCs constitute a promising antiproliferative therapy that has proven to be especially effective against breast cancer.MDPI2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/204200Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/ijms231911310International Journal of Molecular Sciences, 2022, vol. 23https://doi.org/10.3390/ijms231911310cc-by (c) Thiruchenthooran, V. et al., 2022http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2042002026-05-27T06:46:51Z
dc.title.none.fl_str_mv Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriers
title Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriers
spellingShingle Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriers
Thiruchenthooran, Vaikunthavasan
Antiinflamatoris no esteroïdals
Càncer
Nonsteroidal anti-inflammatory agents
Cancer
title_short Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriers
title_full Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriers
title_fullStr Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriers
title_full_unstemmed Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriers
title_sort Novel strategies against cancer: dexibuprofen loaded nanostructured lipid carriers
dc.creator.none.fl_str_mv Thiruchenthooran, Vaikunthavasan
Switalska, Marta
Bonilla Vidal, Lorena
Espina García, Marta
García López, María Luisa
Wietrzyk, Joanna
Sánchez-López, E. (Elena)
Gliszczyńska, Anna
author Thiruchenthooran, Vaikunthavasan
author_facet Thiruchenthooran, Vaikunthavasan
Switalska, Marta
Bonilla Vidal, Lorena
Espina García, Marta
García López, María Luisa
Wietrzyk, Joanna
Sánchez-López, E. (Elena)
Gliszczyńska, Anna
author_role author
author2 Switalska, Marta
Bonilla Vidal, Lorena
Espina García, Marta
García López, María Luisa
Wietrzyk, Joanna
Sánchez-López, E. (Elena)
Gliszczyńska, Anna
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Antiinflamatoris no esteroïdals
Càncer
Nonsteroidal anti-inflammatory agents
Cancer
topic Antiinflamatoris no esteroïdals
Càncer
Nonsteroidal anti-inflammatory agents
Cancer
description The aim of this work was to design innovative nanostructured lipid carriers (NLCs) for the delivery of dexibuprofen (DXI) as an antiproliferative therapy against tumoral processes, and overcome its side effects. DXI-NLC samples were prepared with beeswax, Miglyol 812 and Tween 80 using high-pressure homogenization. A two-level factorial design 24 was applied to optimize the formulation, and physicochemical properties such as particle size, zeta potential, polydispersity index and entrapment efficiency were measured. Optimized parameters of DXI-NLCs exhibited a mean particle size of 152.3 nm, a polydispersity index below 0.2, and high DXI entrapment efficiency (higher than 99%). Moreover, DXI-NLCs provided a prolonged drug release, slower than the free DXI. DXI-NLCs were stable for 2 months and their morphology revealed that they possess a spherical shape. In vitro cytotoxicity and anticancer potential studies were performed towards prostate (PC-3) and breast (MDA-MB-468) cancer cell lines. The highest activity of DXI-NLCs was observed towards breast cancer cells, which were effectively inhibited at 3.4 μM. Therefore, DXI-NLCs constitute a promising antiproliferative therapy that has proven to be especially effective against breast cancer.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/204200
url https://hdl.handle.net/2445/204200
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/ijms231911310
International Journal of Molecular Sciences, 2022, vol. 23
https://doi.org/10.3390/ijms231911310
dc.rights.none.fl_str_mv cc-by (c) Thiruchenthooran, V. et al., 2022
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Thiruchenthooran, V. et al., 2022
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417073766039552
score 15,300724

Similar Items